ClinicalTrials.gg
CompletedNCT00004581Updated Feb 20, 2009

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

A Phase 3 interventional study of Lopinavir/Ritonavir and Nevirapine in HIV Infections, sponsored by Abbott. Completed at 88 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2009-02-20.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing nevirapine in HIV Infections — 1 open to participants now, 1 under way, none of them phase 3. Nevirapine · HIV Infections.

Enrollment
26th of 81
300 · median 142
Phase 3
28 of 82
none open now
Registered
1st of 82
by date
Lead sponsor
1 of 82
Abbott

Among the 82 studies testing nevirapine in HIV Infections, this one is the 26th largest by enrollment of the 81 interventional ones that give a count, is one of 28 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 82 studies testing nevirapine in HIV Infections is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About nevirapine

Nevirapine: first FDA approval 1996 (VIRAMUNE), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing nevirapine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include a new protease inhibitor, ABT-378, combined in a capsule with ritonavir (RTV).

Read the detailed description

Patients receive 1 of the following:

  1. ABT-378/RTV plus NVP plus 2 NRTIs; or
  2. Investigator-selected PI(s) plus NVP plus 2 NRTIs.
03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug Therapy, Combination
  • Nevirapine
  • HIV Protease Inhibitors
  • Ritonavir
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • ABT 378
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 12 years old.
  • Are -positive and have a viral load (level of HIV in the blood) of 1,000 - 100,000 copies/ml.
  • Are currently taking an anti-HIV drug combination that includes 1 PI and 2 NRTIs, and that has not been changed in at least 12 weeks.
  • Are naive to (have never taken) at least 1 NRTI, other than zalcitabine or abacavir.
  • Agree to abstinence or use of an effective barrier method (e.g., condom) of .

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have an active illness.
  • Have received treatment for any active opportunistic (AIDS-related) infection within 30 days of study entry.
  • Have ever received a nonnucleoside reverse transcriptase inhibitor (NNRTI).
  • Have received (not yet approved by the FDA) drugs within 30 days of study entry.
  • Have received treatment with a PI other than their current PI.
  • Are receiving chemotherapy for cancer.
  • Are pregnant or breast-feeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
300 participants

Interventions

06

Study locations

88 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Phoenix Body Positive
    Phoenix, Arizona 85016, United States
  • Pacific Oaks Med Group
    Beverly Hills, California 90211, United States
  • Orange County Ctr for Special Immunology
    Fountain Valley, California 92708, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 900276069, United States
  • Tower ID Med Associates
    Los Angeles, California 90048, United States
  • UCLA CARE Ctr
    Los Angeles, California 90095, United States
  • San Francisco Veterans Administration Med Ctr
    San Francisco, California 94121, United States
  • Harbor - UCLA Med Ctr
    Torrance, California 90502, United States
  • Yale Univ / AIDS Clinical Trials Unit
    New Haven, Connecticut 06510, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Infectious Disease Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Emory Univ
    Atlanta, Georgia 30308, United States
  • Cook County Hosp
    Chicago, Illinois 60612, United States
  • AIDS Research Alliance - Chicago
    Chicago, Illinois 60657, United States
  • Division of Inf Diseases/ Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Univ of Kansas School of Medicine
    Wichita, Kansas 67214, United States
  • Tulane Univ Med School
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hosp
    Baltimore, Maryland 21205, United States
  • Boston Med Ctr
    Boston, Massachusetts 02118, United States
  • Community Research Initiative of New England
    Brookline, Massachusetts 02445, United States
  • Univ of Michigan Hospitals and Health Ctrs
    Ann Arbor, Michigan 481090378, United States
  • Abbott Northwestern Hosp
    Minneapolis, Minnesota 55407, United States
  • Saint Michael's Med Ctr / Dept of Infectious Diseases
    Newark, New Jersey 07102, United States
  • St Michaels Med Ctr
    Newark, New Jersey 07102, United States
  • Beth Israel Med Ctr
    New York, New York 10003, United States
  • Cornell Clinical Trials Unit - Chelsea Clinic
    New York, New York 10011, United States
  • Howard Grossman
    New York, New York 10011, United States
  • SUNY / Health Sciences Ctr at Stony Brook
    Stony Brook, New York 117948153, United States
  • SUNY at Stony Brook / Div of Infectious Disease
    Stony Brook, New York 117948153, United States
  • Duke Univ Med Ctr / Infectious Disease Clinic
    Durham, North Carolina 27710, United States
  • Holmes Hosp / Univ of Cincinnati Med Ctr
    Cincinnati, Ohio 452670405, United States
  • Associates in Med and Mental Health
    Tulsa, Oklahoma 74114, United States
  • Oregon Health Sciences Univ
    Portland, Oregon 972109951, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Stephen Hauptman
    Philadelphia, Pennsylvania 19107, United States
  • The Miriam Hosp
    Providence, Rhode Island 02906, United States
  • Oaklawn Physicians Group
    Dallas, Texas 75219, United States
  • Univ of Texas Southwestern Med Ctr
    Dallas, Texas 75235, United States
  • Univ of Texas / Med Branch at Galveston
    Galveston, Texas 775550835, United States
  • Joseph C Gathe
    Houston, Texas 77004, United States
  • Univ of Utah Med School / Clinical Trials Ctr
    Salt Lake City, Utah 84108, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22203, United States
  • Univ of Virginia Health Sciences Ctr
    Charlottesville, Virginia 22908, United States
  • Univ of Wisconsin
    Madison, Wisconsin 53792, United States
  • Royal Brisbane Hosp
    Herston, Australia
  • Pulmologisches Zentrum Der Stadt Wien
    Wien, Austria
  • Hosp Evandro Chagas Fioernz
    Manguinhos RJ, Brazil
  • Castelo
    Sao Paulo, Brazil
  • Fundacao Zerbini Casa Da Aids
    Sao Paulo, Brazil
  • Hosp Do Servidor Publico Estadual De Sao Paulo
    Sao Paulo, Brazil
  • Hosp Heliopolis
    Sao Paulo, Brazil
  • Saint Paul's Hosp
    Vancouver, British Columbia, Canada
  • Ottawa General Hospital
    Ottawa, Ontario, Canada
  • Sunnybrook Health Science Ctr
    Toronto, Ontario, Canada
  • Toronto Gen Hosp
    Toronto, Ontario, Canada
  • Clinique Medicale du Quartier Latin
    Montreal, Quebec, Canada
  • Clinique Medicale L'Actuele
    Montreal, Quebec, Canada
  • Montreal Chest Institute
    Montreal, Quebec, Canada
  • Righospitalet
    Copenhagen, Denmark
  • Hvidovre Univ Hosp
    Hvidovre, Denmark
  • Odense Univ Hosp
    Odense C, Denmark
  • Groupe Hospitalier Bichat-Claude Bernard
    Paris Cedex 18, France
  • CHU De Bicetre
    Paris, France
  • Hopital Gustave Dron
    Tourcoing, France
  • Hopital Paul Brousse
    Villejuif, France
  • EPIMED
    Berlin, Germany
  • Heinrich Heine Universitat
    Dusseldorf, Germany
  • Klinikum Der Johann Wolfgang Goethe Universitat
    Frankfurt, Germany
  • Allgemeines Krankenhaus St Georg
    Hamburg, Germany
  • Univ Zu Koeln
    Koeln, Germany
  • Aids Study Group Mannheim
    Mannheim, Germany
  • Ctr of AIDS Diagnosis and Treatment
    Warszawa, Poland
  • Ponce Univ Hosp
    Ponce, 00731, Puerto Rico
  • Miller
    Belford Gardens, South Africa
  • Cyrildene
    Johannesburg, South Africa
  • Hosp Germans Trias I Pujol
    Barcelona, Spain
  • Hosp Carlos III
    Madrid, Spain
  • Hosp De Mostoles
    Madrid, Spain
  • Hosp Doce De Octubre
    Madrid, Spain
  • Hosp La Paz
    Madrid, Spain
  • Hosp Virgen Del Rocio
    Sevilla, Spain
  • Universitatsspital Zurich
    Zurich, Switzerland
  • Brighton Gen Hosp
    Brighton, United Kingdom
  • Chelsea and Westminster Hosp
    London, United Kingdom
  • Imperial College School of Medicine
    London, United Kingdom
  • Royal Free Hosp
    London, United Kingdom
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00004581
Lead sponsor
Abbott
First posted
Aug 31, 2001
Last update
Feb 20, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nevirapine

Start the discussion